Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Atossa Therapeutics Inc ATOS

Healthcare Biotechnology
Atossa Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It is engaged in developing medicines in areas of significant unmet medical need in oncology with a focus on using (Z)-endoxifen to prevent and treat breast cancer. Its lead drug candidate under development is oral (Z)-endoxifen, which it is developing for both the prevention and treatment of breast cancer. (Z)-endoxifen... see more

Recent & Breaking News (NDAQ:ATOS)

Atossa Genetics Receives Second Positive Safety Committee Decision in Phase 1 Topical Endoxifen Dose Escalation Study

Marketwired May 10, 2017

Atossa Genetics Receives Approval from Institutional Review Board for Continuation of its Fulvestrant Microcatheter Phase 2 Study

Marketwired May 9, 2017

Atossa Genetics Receives Positive Interim Review From Independent Safety Committee in Phase 1 Endoxifen Dose Escalation Study

Marketwired April 20, 2017

Atossa Genetics Enrolls First Cohort of Eight Subjects in Endoxifen Study

Marketwired April 4, 2017

Atossa Genetics Closes Public Offering

Marketwired April 3, 2017

Mid-Morning Market Update: Markets Mostly Lower; Paychex Profit Tops Views

Benzinga.com  March 29, 2017

Atossa Genetics, Inc. Prices $4,000,000 Public Offering

Marketwired March 29, 2017

Atossa Genetics Opens Enrollment in Study of Endoxifen

Marketwired March 23, 2017

Atossa Genetics Provides Update on its Phase 2 Study of Fulvestrant Administered with its Microcatheter

Marketwired January 9, 2017

Atossa Genetics to Present at the 9th Annual Biotech Showcase Conference on January 9, 2017

Marketwired January 5, 2017

Atossa Genetics Appoints Jack Cuzick, PhD, FRS, FMedSci, FRCP (hon) as Scientific Advisor

Marketwired December 23, 2016

Atossa Genetics to Present at the 9th Annual LD Micro Main Event Conference on December 7, 2016

Marketwired December 1, 2016

Atossa Genetics Announces Third Quarter 2016 Financial Results and Provides Company Update

Marketwired November 14, 2016

Atossa Genetics to Provide Company Update and Discuss Third Quarter 2016 Financial Results on Conference Call on Monday, November 14, 2016

Marketwired November 10, 2016

Atossa Genetics Inc. to Present at Upcoming Investor Conferences in October 2016

Marketwired October 14, 2016

Atossa Genetics, Inc. Regains Compliance With NASDAQ Listing Requirement

Marketwired September 13, 2016

Atossa Genetics, Inc. to Present at Upcoming Investor Conferences in September 2016

Marketwired September 12, 2016

Mid-Afternoon Market Update: Crude Oil Down 3.5%; AeroVironment Shares Decline On Q1 Results

Benzinga.com  August 31, 2016

12 Biggest Mid-Day Losers For Wednesday

Benzinga.com  August 31, 2016

Worst Performing Industries For August 31, 2016

Benzinga.com  August 31, 2016